Impact of sociodemographic characteristics and drug-related side effects on quality of life of patients with hepatocellular carcinoma receiving sorafenib treatment in Iraqi hospitals
Background: Sorafenib is an oral multikinase inhibitor which has been given approval by the United States Food and Drug Administration for the treatment of patients diagnosed with hepatocellular carcinoma and advanced renal cell carcinoma . However, measuring quality of life and patient-reported sy...
Main Authors: | Tuqa H. Qasim, Mazin J. Ibraheem, Mohammed Abdul- Hassan Jabarah |
---|---|
Format: | Article |
Language: | English |
Published: |
College of Medicine University of Baghdad
2023-01-01
|
Series: | مجلة كلية الطب |
Subjects: | |
Online Access: | https://iqjmc.uobaghdad.edu.iq/index.php/19JFacMedBaghdad36/article/view/2009 |
Similar Items
-
Treatment outcomes of advanced hepatocellular carcinoma in real‐life practice: Chemotherapy versus multikinase inhibitors
by: Songporn Oranratnachai, et al.
Published: (2023-02-01) -
Sorafenib in the treatment of advanced hepatocellular carcinoma
by: Mousa Ali
Published: (2008-01-01) -
THE USE OF SORAFENIB (NEXAVAR) IN TREATMENT OF PATIENT WITH DISSEMINATED PARATHYROID CANCER: A CASE REPORT
by: V. A. Gorbunova, et al.
Published: (2017-04-01) -
Side skin reactions of multikinase inhibitors in treatment of thyroid cancer
by: F. S. Sevryukov, et al.
Published: (2021-01-01) -
Optimal sequence of systemic therapy after sorafenib failure in patients with hepatocellular carcinoma
by: Sojung Han, et al.
Published: (2020-07-01)